Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00870948 | Phase 1 BA Study, Single Center With Healthy Volunteers | PHASE1 | COMPLETED | 75 | — | — | Jan 1, 2009 | - | Nov 8, 2010 | 1 | United States |
| Arm | Type | Description |
|---|---|---|
| Regimen A | EXPERIMENTAL | One 100 mg ABT-874 (pre-filled syringe liquid formulation from the 6000 L process) injected subcutaneously in the abdominal region at a 45 degree angle |
| Regimen B | EXPERIMENTAL | One 100 mg ABT-874 (pre-filled syringe liquid formulation from the 6000 L process) injected IV in an arm vein |
| Regimen C | EXPERIMENTAL | One 100 mg ABT 874 (reconstituted lyophilized powder from the 3000 L process) injected subcutaneously in the abdominal region at a 45 degree angle |
| Regimen D | EXPERIMENTAL | One 100 mg ABT-874 (reconstituted lyophilized powder from the 1000 L process) injected subcutaneously in the abdominal region at a 45 degree angle |
| Regimen E | EXPERIMENTAL | 700 mg ABT-874 (reconstituted lyophilized powder from the 3000 L process) in 100 mL 5% dextrose solution IV infusion in an arm vein |
| Name | Type | Description |
|---|---|---|
| ABT-874 | DRUG | See Arm Description for details regarding specific Intervention Description that is attributed to each Arm, respectively. |
Inclusion Criteria: * Subjects must be healthy Exclusion Criteria: * Subjects who are not healthy, enrolled in another study, or who have received ABT-874 previously.